Abstract: Provided is a T lymphocyte. The T lymphocyte expresses a chimeric antigen receptor, and includes an extracellular region. The extracellular region includes a first single-chain antibody, a second single-chain antibody, a first linker peptide, and a CD8 hinge region. The first linker peptide is arranged between the first single-chain antibody and the second single-chain antibody. The first single-chain antibody includes a first heavy chain variable region, a first light chain variable region, and a second linker peptide. The second linker peptide is arranged between the first heavy chain variable region and the first light chain variable region. The second single-chain antibody includes a second heavy chain variable region, a second light chain variable region, and a third linker peptide. The third linker peptide is arranged between the second heavy chain variable region and the second light chain variable region.

Abstract: Provided is an antibody or antigen-binding fragment thereof that can specifically recognize CD22. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence at least 95% identical thereto: a heavy-chain variable region CDR sequence: SEQ ID NOs: 1-15, and a light-chain variable region CDR sequence as shown in SEQ IN NOs: 16-30. The antibody can specifically recognize CD22 and has high affinity to CD22.

Abstract: Provided is a T lymphocyte. The T lymphocyte co-expresses a fusion protein and a chimeric antigen receptor, and the chimeric antigen receptor identifies a tumor antigen, herein the chimeric antigen receptor includes: an extracellular region; a transmembrane region, herein the transmembrane region is connected to the extracellular region, and embedded into a cell membrane of a transgenic lymphocyte; and an intracellular region, herein the intracellular region is connected to the transmembrane region, and the intracellular region includes an immune co-stimulatory molecule intracellular segment. The fusion protein includes: an immune checkpoint single-chain antibody and a T cell activation molecule.

Abstract: Provided is an antibody, which is capable of specifically binding to a B-cell maturation antigen (BCMA). The provided BCMA antibody is capable of specifically binding to an extracellular fragment of the BCMA and has excellent affinity and specificity; and the antibody is a functional antibody and has the activity blocking binding of the BCMA with its ligand APRIL. Immune cells constructed based on the antibody has an excellent specific killing function for a BCMA-positive tumor cell.

Abstract: The present invention relates to the technical field of door closers, and particularly discloses an electromagnetic release door closer. The electromagnetic release door closer comprises a door closer body, a slide rail, and a rocker arm, one end of the rocker arm is articulated with the door closer body, wherein the slide rail is provided with a slide groove and a slide cavity which are parallel to each other, a through slot which is parallel to the slide groove is arranged between the slide groove and the slide cavity, wherein an electromagnetic limiting mechanism can be fixed at any position in the slide cavity.

Abstract: The present invention relates to the technical field of door closers, and particularly discloses an electromagnetic release door closer. The electromagnetic release door closer comprises a door closer body, a slide rail, and a rocker arm, one end of the rocker arm is articulated with the door closer body, wherein the slide rail is provided with a slide groove and a slide cavity which are parallel to each other, a through slot which is parallel to the slide groove is arranged between the slide groove and the slide cavity, wherein an electromagnetic limiting mechanism can be fixed at any position in the slide cavity.